| (+)-Erinacin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| (+)-Magnoflorine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Clerosterol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Isoproterenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-Norgestrel-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (-)-β-Peltatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| (-)-Isoproterenol hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| (2''S)-2'',3''-Dihydrodelicaflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoegomaketone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (2R,3S)-Emricasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (2S,3R,4S)-ASX-173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| (5Z,2E)-CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.03% |
| (Asp)2-Rhodamine 110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-[8]-Shogaol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (E)-Ethyl p-methoxycinnamate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| (E/Z)-Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| (Iso)-Z-VAD(OMe)-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (R)-Sulforaphane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| (Rac)-M826 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| (Rac)-PEAQX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Rac)-Z-FA-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (Z-IETD)2-Rh 110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (±)-Naringenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| 1,3,5-Tricaffeoylquinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Monopalmitin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| 1-Monopalmitin-d31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| 10-Hydroxy-2-decenoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| 10-Hydroxydecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| 13'-Carboxy-δ-tocopherol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 14-Deoxyandrographolide (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 15-Acetoxyscirpenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| 17-Hydroxy sprengerinin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| 2'-Deoxyadenosine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| 2'-Deoxyadenosine monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| 2'-Deoxyadenosine monohydrate-1′-13C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine monohydrate-13C10,15N5 hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.7% |
| 2'-Deoxyadenosine monohydrate-15N5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine monohydrate-2′-13C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine monohydrate-3′-13C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine monohydrate-5′-13C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine-13C10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| 2'-Deoxyadenosine-13C10,15N5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine-15N1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2'-Deoxyadenosine-15N5,d13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2,5-Hexanedione-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| 2-Aminobenzothiazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| 2-Et-AZT |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-HBA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| 2-Hexadecanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 2-Methoxyjuglone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2-Chlorohexadecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| 2-Methoxycinnamaldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 20-5,14-HEDE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| 20-5,14-HEDE-d2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 20-5,14-HEDE-d2-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 20-5,14-HEDE-d2-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 23-Hydroxybetulinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| 28-Deoxonimbolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 3′,4′,7-Trihydroxyflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.04% |
| 3-Methoxy-9H-Carbazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| 3-O-Methylgallic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| 4'-Bromo-resveratrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| 4′-Hydroxywogonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.22% |
| 4′-O-Methylglabridin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| 4,4′-Secalonic acid D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 4-Methoxycinnamic acid ethyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.72% |
| 4-Methylthiazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Caspase-3-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 5,7,4'-Trimethoxyflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.21% |
| 5,7-Dihydroxy-4-methylcoumarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| 5,7-Dihydroxychromone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| 6,8-Diprenylorobol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| 6-Methoxydihydrosanguinarine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oxidopamine hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.42% |
| Oxidopamine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| 7-Oxogedunin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 7DG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| 8-Gingerol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Barlerin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| 9-cis-Canthaxanthin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A-1155905 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| A2AR/EGFR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-AAVALLPAVLLALLAP-DEVD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-AAVALLPAVLLALLAP-LEHD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-AAVALLPAVLLALLAP-LEVD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-AAVALLPAVLLALLAP-YVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-AAVALLPAVLLALLAPVAD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-Asp-Glu-Val-Asp-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-ATS010-KE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-DEVD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Ac-DEVD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-DEVD-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.81% |
| Ac-DEVD-CMK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| Ac-DEVD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Ac-DMLD-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-DMLD-CMK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| Ac-DMQD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-DMQD-AMC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-DMQD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-DNLD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-FLTD-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Ac-IEPD-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Ac-IEPD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Ac-IETD-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ac-IETD-AFC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-Ile-Glu-Thr-Asp-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| Ac-LDESD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-LEHD-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Ac-LEHD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Ac-LEHD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-LETD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-LEVD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| Ac-LEVD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-LEVD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.17% |
| Ac-LEVDGWK(Dnp)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AC-P19M |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-Trp-Glu-His-Asp-Aldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-Trp-Glu-His-Asp-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Ac-Tyr-Val-Lys-Asp-aldehyde |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Ac-VAD-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VAD-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VAD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VDQQD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VDVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VDVAD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Ac-VDVAD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VEID-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ac-VEID-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VEID-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Ac-VEID-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VETD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VRPR-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-VRPR-AMC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| Ac-WEHD-AFC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Ac-WEHD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Ac-YVAD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Ac-YVAD-AOM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-YVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.99% |
| Ac-YVAD-CHO acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-YVAD-cmk |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Ac-YVAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ac-YVAD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Acetic acid lead |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetoxycycloheximide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetyl dipeptide-1 cetyl ester |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.11% |
| Acetyl zingerone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Acetyl-L-carnitine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Acetyl-L-carnitine hydrochloride-13C3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AChE-IN-105 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acrofolione A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AD-2646 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ADP-β-S trilithium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
94.9% |
| ADP-β-S trisodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGN 192403 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AGN 192403 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| AKN-028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| AKN-028 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.38% |
| AKN-028 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AKT-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Akt/mTOR-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AKT1-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Akt1/Akt2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.01% |
| ALC67 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ALK-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| ALKBH5-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Almorexant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Almorexant hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| AMG-337 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Aminoflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amsacrine isethionate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Amsacrine lactate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anhydrohirundigenin mono-thevetoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aniline mustard |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Anti-CD146 Antibody (AA98) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Human/Mouse CD95 Antibody (HFE7A) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-Inflammatory Caspase Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anti-ITGB1 Antibody |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.16% |
| anti-TNBC agent-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiangiogenic agent 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiangiogenic agent 9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 157 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 223 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 269 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 296 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 310 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 311 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 325 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.58% |
| Anticancer agent 56 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 58 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Anticancer agent 64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antioxidant agent-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antiproliferative agent-42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-196 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Antitumor agent-72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| API-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Apoptosis inducer 19 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Apoptosis inducer 30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Apoptosis inducer 43 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 50 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptosis inducer 56 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptotic agent-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Apoptotic agent-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.19% |
| AR Degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ARRY-380 analog |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| AS1604498 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ASP3026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Aspidin BB |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Aspirin calcium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aspirin lithium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Astin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| ASTX295 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| ASX-173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Atiprimod |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Atiprimod dimaleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Atiprimod hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ATWLPPRAANLLMAAS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| AVN-944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| AZ-10417808 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Azoramide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Aβ aggregation-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| BAG3/HSP70-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bax activator-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BBR-BODIPY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.15% |
| BC-1471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Bcl-2-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bcl-2/Mcl-1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BD-AcAc2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Belnacasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| BEPP hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Berkeleyamide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berkeleyamide C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berubicin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
85.02% |
| Berubicin hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.08% |
| Berzosertib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Berzosertib hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.77% |
| Bfl-1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| Bfl-1-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bfl-1-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BG45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| BIM-46174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Biotin-DEVD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Biotin-DEVD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BKT300 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BLT1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BM-1244 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Boc-AEVD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| Boc-AEVD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Boc-Ala-Ala-Asp-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.05% |
| Boc-Asp(OBzl)-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Boc-Asp(OMe)-fluoromethyl ketone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| BOC-D-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| BPTQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BRD-810 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.00% |
| BRD4 Inhibitor-15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Brevetoxin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Briciclib sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BT-PROTAC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BTK-IN-47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BTX306 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BV02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| BW-AQ-113 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BWA-6047 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| BYBC-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c-MYC/BCL2 ligand 1 iodide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C-Reactive Protein (CRP) (174-185) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| C105SR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| C14-Tri-LAN-Gly |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| c9,t11,c15-CLNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CA IX/VEGFR-2-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAIX/CDK-2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cajanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Calactin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Candidone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cardanol monoene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Carteolol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP12 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp12 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp12 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP2 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp2 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp2 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP3 activator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP3 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp3 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP4 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp4 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp4 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP6 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp6 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP6 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP7 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp7 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp7 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP8 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp8 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp8 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CASP8-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.97% |
| CASP9 Human Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp9 Mouse Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Casp9 Rat Pre-designed siRNA Set A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3 activator 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3 activator 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3 activator 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3 activator 5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.13% |
| Caspase-3-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3/7 activator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3/7 activator 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3/7 activator 3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3/7 activator 4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-3/7 Inhibitor I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| Caspase-4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caspase-9 Inhibitor III |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| Casuarinin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.24% |
| Cathepsin-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAY10406 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CB2 receptor agonist 8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD00509 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| CDC25-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK1/2/4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK4/6-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK6-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK9-IN-42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK9-IN-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDK9-IN-47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CDPPB |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.01% |
| Cedrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Chlorin e6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| Chlorin e6 (solution) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CHNQD-00824 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CHNQD-01426 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CHNQD-01522 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chuanbeinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CIDD-8633 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cimiside E |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CK2-TN03 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Clausenidin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cosdosiran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| Cosdosiran sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| Cosdosiran sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX-2-IN-55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.20% |
| COX-2-IN-59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| COX/5-LO-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CQ31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| cRIPGBM chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| CSN5-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CT-179 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.61% |
| CU-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cucurbitacin F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Curcumin monoglucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CyGbPF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cystamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Cystamine dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Cystamine-d8 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cytochalasin H |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| CZL55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| CZL80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.31% |
| d-(KLAKLAK)2, Proapoptotic Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| d-(KLAKLAK)2, Proapoptotic Peptide acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.21% |
| d-KLA Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| d-KLA Peptide-d30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| D-Leucine amide-CDDO-Me-HMP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| d-T101 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Daphnoretin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| dCASP1-55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| dCDK9-202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| DdBIC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deacetyltanghinin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DeFer-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
| Dehydrocorydaline (hydroxyl) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.52% |
| Deltamethrin-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Demethoxyfumitremorgin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DH20931 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DHODH-IN-32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dicatenarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Difopein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Difopein TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.35% |
| DIM-3,5-Cl2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Dimethyl bisphenolate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dimethyl tetrasulfide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Diuvaretin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| dMCL1-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| DNH28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DNMT-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DpC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.73% |
| DPQZ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DTB-acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Duocarmycin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| DY-9760e |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| E7974 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Echinoside A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ecubectedin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.59% |
| ED11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EF24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Eftozanermin alfa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.86% |
| EGFR-IN-109 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-134 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-182 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-186 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-191 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-197 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR-IN-214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/BRAFV600E-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/CA-IX-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/CDK2-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/HER2-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/HER2-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/VEGFR2-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EGFR/VEGFR2-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Elevenostat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.07% |
| EM20-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EMT inhibitor-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| EP1013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ERK1/2 inhibitor 11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ERK5-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Esmolol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estrogen receptor modulator 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Euphornin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| Euptox A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FAK-IN-28 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FASN-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ferroptosis/apoptosis inducer-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FGFR-IN-25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FGFR3-IN-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FKA-9i |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FLC-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fluazinam |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Fluorescein-6-carbonyl-Asp(OMe)-Glu(OMe)-Val-DL-Asp(OMe)-fluoromethylketone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FMP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forsythoside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| FS102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FTI-277 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FTI-277 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| FuBIG |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganoderic acid Mk |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ganoderic acid T1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GD3 Ganglioside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GD3 Ganglioside (bovine brain) sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GD3 Ganglioside (bovine buttermilk) ammonium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GDC-2394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| GDC-2394 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GEA 3162 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| GEA 3162 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Geiparvarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ginkgo biloba extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ginsenoside F2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| GlcNAc-MurNAc |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.37% |
| Glufosfamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Glycocholic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Glycocholic acid hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Glycocholic acid sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| Glycocholic acid-13C2,d4N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Glycocholic acid-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Gomisin N |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Gossypin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| GPR |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GPS167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GRI977143 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| GSPT1 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| GUT-70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Haplophytin-A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| hCAIX-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hck-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-94 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC-IN-99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC1-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC1-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC1-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC1-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC1/6-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC3 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC3 degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC3-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC6-IN-63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC6-IN-67 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC8-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HDAC9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.13% |
| HDSI-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hibiscetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HIF-2α-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HL435 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HLC40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HMGB1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HS-72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HSP70-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HTS07944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hydroquinone-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ICA-1S |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Icariside I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.76% |
| ICD inducer-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Idasanutlin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| IDN-1965 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDN-7314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IDO1-IN-34 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IETD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IETD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IETDC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IGN523 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.47% |
| IHMT-BMX-068 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ILK-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| iMPZ-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inclisiran sodium scrambled negative control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| INH2BP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Inotodiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| IPH10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IRF1 antagonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.87% |
| IRF1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| IRF1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Ironomycin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| ISAM-CG557 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isoandrographolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| Isocryptotanshinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Isolinderalactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.79% |
| Isomahanine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ivachtin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| JAB-2485 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| JAK1/2-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JAK1/CDK7-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| JP-11646 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.74% |
| JQAD1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.24% |
| Kamebakaurin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| KDM1/CDK1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KEA1-97 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.05% |
| KLA peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KLA peptide acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Kp7-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| KRAS G12D-IN-37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| KTt-45 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Kumatakenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Kushenol Z |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| L-Selenocystine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| L67 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| L6H21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Lb54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LD5097 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LIB3S0280 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Licoflavanone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ligandrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Limonin glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LJ-2698 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LM-021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.27% |
| Loliolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Lometrexol disodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Longan cerebroside II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LPT99 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LQFM030 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LSD1-IN-26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LWY713 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ly101-4B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lycopodine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lysosomal P-gp targeted agent 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M190S |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| M464 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| M802 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M826 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| M867 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MA203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Magnesium isoglycyrrhizinate hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| MAPK-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MAPK-IN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maxadilan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MC3817 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MC3817 free base |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-DEVDAP-K(Dnp)-OH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-VDQVDGW-Lys(Dnp)-NH2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-YVADAP-Lys(Dnp)-OH |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mca-YVADAP-Lys(Dnp)-OH TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| MCB-294 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MCB-36 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| Mcl-1-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mcl-1-IN-23 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ME-344 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| MEB55 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Met-12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.66% |
| Methyl pheophorbide a |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Metuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Microtubule destabilizing agent-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Microtubule destabilizing agent-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MKI-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MKK7-JNK activator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| ML132 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.43% |
| MM41 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.89% |
| MMP-9-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MMPSI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| MN33-47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MN33-63 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MNK/PIM-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MNP2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MO-2097 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mofarotene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Monascuspiloin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Moroxydine hydrochloride-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mouse Serum Albumin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| MPT0B214 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MPT0B392 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| MRTX849-amide-C4-(o)-carborane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MS1129 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MS6076 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MST3-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MST3-IN-1 TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| MT-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mulberrofuran G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.86% |
| Multi-kinase-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Multi-kinase-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MX1013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.04% |
| Myrothecine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N,N'-Methylenebisacrylamide-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N,N'-Methylenebisacrylamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| N-(p-Coumaroyl) Serotonin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.03% |
| N-(p-Coumaroyl) Serotonin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-3-oxo-dodecanoyl-L-homoserine lactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| N-Acetyl-L-methionine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| N-Acetyl-L-tryptophan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| N-Acetyl-L-tryptophan-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N-Nitrosodibutylamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| N-Hydroxyphthalimide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| N-Hydroxyphthalimide (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| N1,N11-Diethylnorspermine hydrobromide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| N1,N11-Diethylnorspermine tetrahydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| NCO-141 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NCO-90 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NCP26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NDI-Lyso |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Necrosulfonamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.61% |
| Necrosulfonamide-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Nef-M1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NEK7 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| NEK7 degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Neral |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.87% |
| NEURL1B-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Neuroprotective agent 11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Neuroprotective agent 15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Neuroprotective agent 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nivocasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NKP608 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| NL13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3 agonist 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| NLRP3-IN-81 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-84 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-87 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NLRP3-IN-91 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NN3201 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.15% |
| Nordentatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NOTA-GZP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NP-1815-PX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NP-1815-PX sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.51% |
| NP3-146 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NP3-146 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| NPS 2390 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| NPT100-18A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Nrf2 activator-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC 850745 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC12 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC194598 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.90% |
| NSC647889 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| NSC666715 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NSC745887 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| NWL-117 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ofirnoflastum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| OH14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ombuoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Oosporein |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.16% |
| Orellanine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Orsellinic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| Orsellinic acid (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ossirene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| OT-82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Oxidized low density lipoprotein (Human) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Oxychlororaphine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.63% |
| p-nitro-Pifithrin-α |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.0% |
| p38α inhibitor 6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PAC-1-d8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PARP-1-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.48% |
| PARP-1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| PARP1-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PAWI-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.29% |
| PbQ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PDGFRA/CAIX/XII-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| PEAQX |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PEAQX tetrasodium hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Penicillic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| Pentadecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Peptide E5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Periplanetasin-4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PeS-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PETCM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| PFKFB4-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| PHA-690509 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PHA-793887 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Phenoxodiol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Phoyunbene B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI-1840 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.78% |
| PI3K/Akt/mTOR-IN-7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3K/mTOR-IN-22 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PI3Kδ/HDAC6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pim-1 kinase inhibitor 10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pim-1 kinase inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Pim-1 kinase-IN-14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pinusolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Pipernonaline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| PKM2-IN-13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Porphyra 334 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| PP5-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| PPIA-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.90% |
| PQ-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PQ-1 succinate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pralnacasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Prion Protein (118-135), human |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Procaspase-3 activator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Procaspase-3/6 activator 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Procyanidin B2-3'-O-gallate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prostaglandin A2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| PROTAC ATR degrader-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC BCL6/GSPT1 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC BRD4 Degrader-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC CDK2/4/6 Degrader-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC EZH2 Degrader-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC FTO degrader 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC IKKβ/NR4A1 degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PROTAC K-Ras Degrader-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.04% |
| Protectin D1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Protoapigenone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| PRT062607 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.38% |
| PRX-08066 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.46% |
| PRX-08066 maleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| PTD10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.38% |
| PZ-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Q-Peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.46% |
| Q-VD-OPh |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Q-VD-OPh |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| QM31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.00% |
| QS-21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.93% |
| QS-21-Api |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Quercetin-3'-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| Quinalizarin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.23% |
| RAPTA-C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Raptinal |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Relaxin H3 (human) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Relaxin H3 (human) TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reproxalap |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.49% |
| Reproxalap (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RGD peptide (GRGDNP) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| RMC-4745 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RN-0001 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ROS-generating agent 1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.11% |
| Roxatidine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.25% |
| RP-182 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.68% |
| RP-182 acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RPS6-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| RSM3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.73% |
| S-Petasin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| S1QEL1.1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Sanazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sanggenon G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.33% |
| Santamarine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.85% |
| Sarglaroids F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Satratoxin G |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.5% |
| Satratoxin H |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.7% |
| SBP-5147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SC-60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SDZ 224-015 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.05% |
| Selenocystine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99% |
| Senkyunolide I |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.37% |
| SF-9-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SF5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| SHetA2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Simotaxel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SK2188 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| SKLB-Y13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.44% |
| SKLB70326 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SL-176 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| SM1044 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Smac-N7 peptide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.88% |
| Smac-N7, Penetratin conjugated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMO-IN-6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SMU-G4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SP-6-27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sphingosine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SRSF1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ssRNA40 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.34% |
| ST-168 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ST09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3-IN-44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3/CAIX-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STAT3/NF-κB-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stigmalactam |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stigmast-5-en-3-ol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STING-IN-17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STK899704 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Strictinin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.15% |
| SU212 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SV119 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| SYM 2081 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Tambiciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Tambiciclib dimaleate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Tambulin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TASIN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.09% |
| TASIN-1 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TBC1D2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TC11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.55% |
| TCF4/β-catenin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TD1092 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| TFGF-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Thevetiaflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Tigilanol tiglate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96.35% |
| TKL002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TMI-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| TMLB-C16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.27% |
| TNF-α-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topo I/II-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topo I/II-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I inhibitor 2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I-IN-18 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase I/II-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase II-IN-24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Topoisomerase II/EGFR-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TP-110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| trans-Trimethoxyresveratrol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |
| Trehalose-6,6'-dibehenate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Trifloxystrobin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Trijuganone C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trilexium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Triphenyltin(IV) diisopropyl dithiocarbamate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triptolidenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Troponin-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TRP-601 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TrxR1-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TrxR2-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tryptophol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Tryptophol-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| TS-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-68 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-82 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin polymerization-IN-89 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tubulin/LSD1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| TZ3O |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.17% |
| TZEP7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| UC-112 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.92% |
| URAT1-IN-16 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| USP7-IN-20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vacquinol-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.33% |
| VCP/p97 IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-69 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2-IN-70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR-2/AKT-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VEGFR/PD-L1-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vicanicin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vitexin-4''-O-glucoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Vitisin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
96% |
| VMY-1-103 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VRT-043198 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.66% |
| VS1150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| VX-166 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WCF-598 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WF-210 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WP-1034 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| WS-384 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.23% |
| XAN-5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Xanthoangelol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Xelafaslatide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| XIAP-CASP7 PPI-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YCH3971 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YTHu78 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YVAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| YVAD-CHO TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.48% |
| YVPGP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-AEVD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Z-Ala-Ala-Asp-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Z-Asp(OMe)-Gln-Met-Asp(OMe)-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-Asp-CH2-DCB |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.64% |
| Z-ATAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-DEVD-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.08% |
| Z-DEVD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.18% |
| Z-DEVD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-DEVD-R110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-FA-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.14% |
| Z-FF-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.98% |
| Z-IETD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-IETD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-LE(OMe)TD(OMe)-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-LEED-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-LEHD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-LEHD-FMK TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-LEVD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-TPE-2DEVD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VA-DL-D-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VAD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Z-VAD(OMe)-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-VAD-AMC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| Z-VAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VDVA-(DL-Asp)-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VDVAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-VEID-AFC |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VEID-AFC TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-VEID-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Z-WEHD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-YVAD-CMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Z-YVAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Z-YVAD-pNA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZAK-IN-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zaptuzumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.0% |
| Zenidolol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.60% |
| ZIF-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZM484 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZSTK3744 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZSTK3744 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZX079 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ZYZ-488 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| α-D-Glucosyl hesperidin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α-Santalol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.62% |
| α-Amyrin acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| α-Amyrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| α-Amyrin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| α5β1 integrin agonist-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| β-Carotene-15,15'-epoxide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Patchoulene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Santalol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| β-Eudesmol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.49% |
| Crustecdysone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Beta-Sitosterol (purity>98%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| δ-Secretase inhibitor 11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| δ-Tocotrienol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.10% |
| Notoginsenoside R2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Triclabendazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Sodium acetate trihydrate, 99.5% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Prosultiamine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pretilachlor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.25% |
| Hexane-2,5-dione |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Salvianolic acid D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.15% |
| Salvianolic acid F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.30% |
| Ru(acac)3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Acetyl-L-carnitine-d3 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Acetyl-L-carnitine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Acetyl-L-carnitine-d3-1 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Ac-VAD-CHO |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Acetic Acid-13C,d3-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acetic acid-d1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sodium acetate trihydrate, meets analytical specification of Ph. Eur. BP USP FCC E262, ≤0.00002% Al |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100.4% |
| Sodium acetate trihydrate, United States Pharmacopeia (USP) Reference Standard |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Magnesium acetate tetrahydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| Sodium glycocholate hydrate, 98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Copper(II) diethyldithiocarbamate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.5% |
| N1,N11-Diethylnorspermine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydroactinidiolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Dihydrocapsaicin-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dihydrocapsaicin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Pendimethalin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Copper sulfate pentahydrate, 99.9% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Copper sulfate pentahydrate, for cell culture, 98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Sodium Selenite |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.00% |
| Ginsenoside Rh2 (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98% |
| Ginsenoside Rh2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Ginsenoside Rh4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.28% |
| Fenobucarb |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.62% |
| Fenobucarb-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lucidin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.03% |
| Perfluorododecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Perfluorodecanoic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| PAC-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Flavokawain A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.73% |
| Flavokawain C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.53% |
| Azadirachtin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.06% |
| Co(III) protoporphyrin IX chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Dehydrocostus Lactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Dehydrotrametenolic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| (S)-(+)-Carvone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.26% |
| Moroxydine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Caudatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Halcinonide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.29% |
| Thiabendazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Denosumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Digitoxin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.18% |
| Rehmannioside D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Karacoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| 2-Hydroxy-3-methylanthraquinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.67% |
| Rhein 8-O-β-D-Glucopyranoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Quinidine (15% dihydroquinidine) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.36% |
| Quinidine-13C, d2 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Quinidine hydrochloride monohydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.97% |
| Quinidine hydrochloride monohydrate (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Quinidine polygalacturonate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Quinidine gluconic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Quinidine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Ospemifene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| AC-45594 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.94% |
| Wheat Germ Agglutinin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Hawthorn Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arnicolide D |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Jolkinolide B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.65% |
| Jolkinolide B (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Asperosaponin VI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Levonorgestrel |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Parishin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.24% |
| Briciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.45% |
| Patuletin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Isosilybin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.94% |
| Isosilybin B (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Angelicin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Dynorphin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.09% |
| Dynorphin A TFA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Emricasan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Guaiazulene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Golimumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Ascorbyl palmitate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.62% |
| Lacidipine-13C4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lacidipine-13C8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lacidipine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.40% |
| Pseudoginsenoside F11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Neoliquiritin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Probucol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Tralokinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.12% |
| Epimedin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.43% |
| Epmedin C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.47% |
| Periplogenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.34% |
| Periplogenin (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gardenin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Phlorizin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Phlorizin dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Hibifolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.70% |
| Phaseoloidin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Fluopyram |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.76% |
| Hydroquinone-d6 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Hydroquinone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Nickel(II) oxide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (+)-Magnoflorine chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.10% |
| Cobalt (ll) chloride hexahydrate, for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.18% |
| Indium(III) chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Zinc chloride, for cell culture |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cypermethrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Tabersonine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.02% |
| Tabersonine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.55% |
| Arenobufagin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.82% |
| Alisol B acetate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Lometrexol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Lometrexol hydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Deltamethrin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Macranthoside B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.95% |
| Macranthoidin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.35% |
| Griseofulvin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.07% |
| Tauroursodeoxycholate-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tauroursodeoxycholate-d4-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tauroursodeoxycholate-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tauroursodeoxycholate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Tauroursodeoxycholate-d4 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tauroursodeoxycholate sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.40% |
| Tauroursodeoxycholate dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Taurochenodeoxycholic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Vitexin-2"-O-rhamnoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Vitexin-2"-O-rhamnoside (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Terfenadine-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Terfenadine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Zerumbone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Daphnetin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Polygalasaponin F |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Glycocholic acid-d5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Glycochenodeoxycholic acid sodium salt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| Licoflavone C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.83% |
| Kansuinine A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Glycochenodeoxycholic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Biotin-VAD-FMK |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.0% |
| Thiophanate-Methyl |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Chelidonic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Moroxydine hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.36% |
| Dehydrocorydaline chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.75% |
| Esmolol hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Dehydrocorydaline nitrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Quinidine sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Quinidine sulfate dihydrate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berberine hemisulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.63% |
| (+)-Magnoflorine iodide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Agnuside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Bromuconazole |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Perillyl alcohol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95.46% |
| Corynoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.84% |
| Cytochrome C (bovine heart) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.9% |
| Cytochrome C (Saccharomyces cerevisiae) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cytochrome C (equine heart) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.1% |
| Lobaplatin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| 1,2,4-Trimethoxybenzene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Madecassoside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.58% |
| Carboxymethyl chitosan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90% |
| Polyporenic acid C (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Polyporenic acid C |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.81% |
| Citicoline (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.19% |
| Citicoline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.57% |
| Citicoline sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.77% |
| Citicoline sodium (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Citicoline-d9 sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.80% |
| Dehydrocorydaline |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.42% |
| Chromomycin A3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.07% |
| Sesamolin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.51% |
| Fenbufen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.50% |
| Fenbufen-d9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benzethonium chloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.47% |
| Sotetsuflavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Benzbromarone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.91% |
| Sulfabenzamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.68% |
| Sulfabenzamide-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.74% |
| Inclisiran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.96% |
| Inclisiran sodium |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.08% |
| Solanesol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Solanesol (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Stem bromelain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Heptelidic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
97.5% |
| Sulforaphane |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.01% |
| Puerarin 6''-O-Xyloside |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.81% |
| Cucurbitacin IIa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.90% |
| Cranberry Extract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prosapogenin A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.88% |
| Bakkenolide A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Agkistrodon halys batroxobin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95% |
| Wedelolactone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.87% |
| Hellebrigenin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Dracorhodin perchlorate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.02% |
| Epifriedelanol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.69% |
| Fucoxanthin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.54% |
| Simazine-d10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Simazine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.44% |
| Peiminine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.89% |
| Coenzyme Q0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.79% |
| Cinchonine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.71% |
| Onjisaponin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.31% |
| Zinc phthalocyanine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.0% |
| Jujuboside B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.92% |
| Methazolamide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.41% |
| Paris saponin VII |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Continentalic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.72% |
| Aspirin-d3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.84% |
| Aspirin-d4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
98.41% |
| Aspirin-d7 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aspirin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Nivalenol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Nivalenol-13C15 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Triptophenolide |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.98% |
| Triptophenolide (Standard) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fezakinumab |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.9% |
| Guggulsterone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.78% |
| Verbenalin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.93% |
| Homoeriodictyol |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.86% |
| Bruceantin |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.67% |
| Flavokawain B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.99% |
| Aflatoxin B1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.96% |
| Berberine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Berberine sulfate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.23% |
| Flavone |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.85% |
| Destruxin B |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99.35% |